ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0755

Providing Multidisciplinary Renal Care in the Time of COVID-19

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Fielding, Ollie, pulseData, New York, New York, United States
  • Son, Jung Hoon, pulseData, New York, New York, United States
  • Yu, Tia Yue, pulseData, New York, New York, United States
  • Bohmart, Andrew, The Rogosin Institute, New York, New York, United States
  • Liu, Frank, The Rogosin Institute, New York, New York, United States
  • Silberzweig, Jeffrey I., The Rogosin Institute, New York, New York, United States

Group or Team Name

  • The PEAK team

New York City (NYC)-based Rogosin Institute has provided a specialty case management to patients via its Program for Education in Advanced Kidney Disease (PEAK) since 2015. PEAK aims to educate patients about options for renal replacement therapy and encourages adoption of home dialysis modalities and transplantation. The global pandemic due to the novel coronavirus SARS-CoV-2 (COVID-19) hit NYC at the beginning of March 2020 and has resulted in over 40,000 hospital admissions and claimed the lives of 15,000 NYC residents.


A city-wide requirement to adopt social distancing caused us to adapt our approach so we could continue our patient management and delay dialysis starts where possible. Our multidisciplinary team continued to provide regular consults via a telehealth platform. pulseData built a query to look at the standard deviation of lab results for creatinine and potassium over the prior six months leading to decreased need for patients to leave their homes for venipuncture. We also built a query to identify those patients at high risk of poor COVID-19 outcomes (those over age 65, with COPD or other respiratory conditions, and other comorbid risk factors). These high risk patients were discussed in a weekly care plan meeting.


The Rogosin team delivered 481 telehealth appointments between January 1 and May 1 2020. We identified 17 of 189 patients seen in PEAK over the last 12 months as high risk for poor COVID-19 outcomes. The standard deviation (SD) of the last six months of serum creatinine measurements for PEAK patients was 0.24 (IQR 0.16-0.44), patients with an SD in the top quintile were considered to be in need of repeat lab tests and home-based venipuncture was used where possible. Only 12 PEAK patients began dialysis treatment between January 1 and May 1 2020 compared with 28 patients in the same period in 2019. Most of these patients (67%) began dialysis optimally (as an outpatient and with venous access) in Jan-May 2020 vs. only 43% in the same period 2019 (a 56% increase).


Responding to the challenges of the COVID-19 crisis were acutely felt in NYC and represented a major disruption to our ability to deliver nephrology care. Adopting a coordinated, data driven approach we were able to continue to deliver multidisciplinary care to patients and improve renal replacement therapy outcomes.


  • Commercial Support